tiprankstipranks
Trending News
More News >
AN2 Therapeutics, Inc. (ANTX)
NASDAQ:ANTX
US Market

AN2 Therapeutics, Inc. (ANTX) Income Statement

Compare
94 Followers

AN2 Therapeutics, Inc. Income Statement

Last quarter (Q3 2025), AN2 Therapeutics, Inc.'s total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, AN2 Therapeutics, Inc.'s net income was $-9.35M. See AN2 Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ -77.00K$ 0.00$ 0.00
Operating Expenses
$ 54.55M$ 69.64M$ 42.19M$ 21.57M$ 7.28M
Depreciation and Amortization
$ 54.55M$ 69.64M$ 77.00K$ 0.00$ 7.28M
EBITDA
$ 3.23M$ 4.90M$ -40.88M$ -21.57M$ -6.32M
Operating Income
$ -54.55M$ -69.64M$ -42.26M$ -21.57M$ -7.28M
Other Income/Expenses
$ 3.23M$ 4.90M$ 1.31M$ 31.00K$ -6.32M
Pretax Income
$ -51.32M$ -64.73M$ -40.96M$ -21.54M$ -13.60M
Net Income
$ -51.32M$ -64.73M$ -40.96M$ -21.54M$ -13.60M
Per Share Metrics
Basic EPS
$ -1.72$ -2.74$ -2.79$ -1.50$ -0.78
Diluted EPS
$ -1.72$ -2.74$ -2.79$ -1.50$ -0.78
Weighted Average Shares Outstanding
29.83M 23.60M 15.34M 18.74M 18.74M
Weighted Average Shares Outstanding (Diluted)
29.83M 23.60M 15.34M 18.74M 18.74M
Currency in USD

AN2 Therapeutics, Inc. Earnings and Revenue History